Cytokine-induced killer cells – Study onset

In March 2016 a multicenter prospective clinical Phase I/II Study investigating the clinical usage of cytokine-induced killer (CIK) cells in patients with high-risk leukemia or myelodysplastic syndromes and expected relapse after allogeneic stem cell transplantation is starting. This immunotherapy study investigates the feasibility, safety and efficiency of IL-15 activated cytokine-induced killer cells. Children and adults can be enrolled. This study is performed in collaboration with the colleagues of Internal Medicine, Goethe University Frankfurt/Main, Gutenberg University Mainz and University Hospital Duesseldorf.